Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Teva Pharmaceutical
Pharma
Aurinia deal with Teva keeps Lupkynis generic in check until '36
Aurinia has struck a patent settlement with Teva that will likely ensure that Lupkynis will not face generic competition in the U.S. until late 2036.
Kevin Dunleavy
Aug 20, 2026 11:28am
J&J’s Tremfya remains on top in Q2 pharma ad spending league
Jul 21, 2026 9:10am
How biosimilar developers are embracing next phase of US market
Jul 6, 2026 10:03am
Teva to lay off 250 at for-sale API unit: report
Jun 10, 2026 10:56am
Teva's innovative drugs helped carry strong Q1
Apr 29, 2026 2:27pm
In Lilly patent spat, appeals court revives $177M verdict to Teva
Apr 17, 2026 10:16am
